RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor-positive Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
Interventions: DRUG: letrozole|DRUG: gamma-secretase/Notch signalling pathway inhibitor RO4929097|PROCEDURE: therapeutic conventional surgery|PROCEDURE: breast biopsy|OTHER: diagnostic laboratory biomarker analysis|OTHER: pharmacological study
Sponsor: National Cancer Institute (NCI)